TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26082815
Drug: Oral levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levosimendan (≥0.5 mg)
Study: 26082815
Drug: Oral levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levosimendan (2.0 mg)
Study: 26082920
Drug: Novel brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel brain and vestibular rehabilitation (VR) treatment for PTSD
Study: 26083135
Drug: Adaptive model-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive model-based dose-ranging trial
Study: 26083256
Drug: Lapatinib 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1500 mg daily in monthly cycles
Study: 26083430
Drug: Therapeutic plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic plasma exchanges (TPE) and rituximab, supplemented with intravenous immunoglobulin (IVIG) in later cases
Study: 26083430
Drug: Conventional glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucocorticoid therapy
Study: 26084934
Drug: Stress Doppler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress Doppler echocardiography (SDE) during low-dose exercise
Study: 26084989
Drug: Alisertib 30
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 30 mg BID
Study: 26084989
Drug: Alisertib 40
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 40 mg BID
Study: 26084990
Drug: Oral MK-2206
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MK-2206 at a dose of 200 mg administered on days 1, 8, 15, and 22 of a 28-day cycle until progression.
Study: 26088649
Drug: Perioperative goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative goal-directed therapy (PGDT) with standardized baseline crystalloid administration of 3 ml/kg/hour and additional boluses based on PGDT.
Study: 26088649
Drug: Perioperative goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative goal-directed therapy (PGDT) implementation.
Study: 26088933
Drug: Ruxolitinib 15
Normalized name: ruxolitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 15 mg orally twice daily plus lenalidomide 5 mg orally once daily on days 1-21
Study: 26088933
Drug: Ruxolitinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib and lenalidomide combination therapy
Study: 26089222
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of oral solithromycin
Study: 26089222
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of oral solithromycin
Study: 26089222
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of solithromycin (1200 mg and 1000 mg)
Study: 26089397
Drug: Combination chemoimmunotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 patients received consolidation radiotherapy.
Study: 26091915
Drug: Ridaforolimus 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg BID days 1-3 weekly (MTD)
Study: 26091915
Drug: Ridaforolimus 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg daily days 1-3 weekly (recommended phase II dose)
Study: 26092537
Drug: Fingolimod therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod therapy
Study: 26093865
Drug: Secondary prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary prevention medications (aspirin, adenosine diphosphate receptor inhibitors, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, statins)
Study: 26094614
Drug: L-asparaginase encapsulated
Normalized name: L-asparaginase encapsulated in red blood cells
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 100 IU/kg
Study: 26094614
Drug: L-asparaginase encapsulated
Normalized name: L-asparaginase encapsulated in red blood cells
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 150 IU/kg
Study: 26094614
Drug: L-asparaginase encapsulated
Normalized name: L-asparaginase encapsulated in red blood cells
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 50 IU/kg
Study: 26094614
Drug: L-asparaginase encapsulated
Normalized name: L-asparaginase encapsulated in red blood cells
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase encapsulated in erythrocytes (GRASPA®)
Study: 26094738
Drug: Pegylated interferon-alpha
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon-alpha plus ribavirin (PegIFN/RBV) therapy
Study: 26094738
Drug: Non-responders with
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders with high MICA level (>100 pg/mL)
Study: 26095521
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy for attenuated MPS I
Study: 26095669
Drug: Alefacept (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (0.25 mg/kg/dose on days -40 and -9; 0.5 mg/kg/dose on days -33, -26, -19, and -12)
Study: 28693366
Drug: Idarucizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (5 g intravenous)
Study: 26095785
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy (35 Gy in ten fractions, over 2 weeks) and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy)
Study: 26095785
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy and granulocyte-macrophage colony-stimulating factor
Study: 26097680
Drug: 300IR 5-grass
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300IR 5-grass pollen tablet (2 months prior to pollen season)
Study: 26097680
Drug: 300IR 5-grass
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300IR 5-grass pollen tablet (4 months prior to pollen season)
Study: 26097680
Drug: Secondary efficacy
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary efficacy measures (both post-treatment years)
Study: 26097986
Drug: AZD3043 1-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3043 1-minute bolus IV infusion (1, 1.5, 2, 4, and 6 mg/kg)
Study: 26097986
Drug: AZD3043 1-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3043 1-minute bolus followed by 30-minute infusion (0.8 + 10, 1 + 15, 3 + 30, and 4 + 40 mg/kg)
Study: 26098143
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon β-1a (Rebif®, Merck Serono SA) 44 or 22 μg three times weekly
Study: 26098215
Drug: Fresolimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresolimumab (1 mg/kg, 2 doses)
Study: 26098215
Drug: Fresolimumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresolimumab (5 mg/kg, 1 dose)
Study: 26098748
Drug: Buparlisib (BKM120)
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (BKM120) 100 mg/day
Study: 26100711
Drug: Paritaprevir-ritonavir dose
Normalized name: ombitasvir / paritaprevir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paritaprevir-ritonavir dose of 150/100 mg
Study: 26100711
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration of 12 or more weeks
Study: 26100711
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration of 8 weeks
Study: 26101247
Drug: Letrozole 5
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 5 mg per day with ovarian stimulation and embryo cryopreservation
Study: 26103565
Drug: Home-based telemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based telemental health treatment (behavioral activation treatment)
Study: 26103598
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg day(-1))
Study: 26105029
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about medications and patient adherence profiles
Study: 26105149
Drug: Initiating treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiating treatment at diagnosis
Study: 26108094
Drug: Laboratory evaluation
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory evaluation and questionnaire administration
Study: 26109588
Drug: guided high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: guided high MI/half tPA (0.5 mg/kg tPA with guided high MI impulses)
Study: 26109588
Drug: full-dose tPA
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: full-dose tPA (1.0 mg/kg tPA)
Study: 26109588
Drug: half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: half dose tPA (control group)
Study: 26109588
Drug: full-dose tPA
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: full-dose tPA
Study: 26109631
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m(2)), Cisplatin (75 mg/m(2)), and Cetuximab (250 mg/m(2) weekly with a loading dose of 400 mg/m(2)), followed by maintenance Cetuximab (500 mg/m(2) every 2 weeks)
Study: 26111297
Drug: Fecal ELISA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal ELISA assay for G intestinalis
Study: 26112004
Drug: Oraxol (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraxol (paclitaxel 150 mg/m(2) per day + HM30181A 15 mg/day)
Study: 26112099
Drug: Self-administered icatibant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered icatibant
Study: 26112099
Drug: HCP-administered icatibant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCP-administered icatibant
Study: 26112223
Drug: Empiric oral
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric oral antibiotic therapy
Study: 26115532
Drug: Unwanted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unwanted treatment (any of the above therapies) in comorbidly depressed patients
Study: 26115532
Drug: Treatment preference/disinclination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment preference/disinclination
Study: 26115532
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment preference
Study: 26116126
Drug: GSK1034702 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1034702 (5 mg oral dose)
Study: 26116126
Drug: [(11)C]GSK1034702 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(11)C]GSK1034702 (intravenous injection)
Study: 26116238
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with Paclitaxel and Trastuzumab for HER2-positive patients
Study: 26116238
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with Docetaxel and Epirubicin for HER2-negative patients
Study: 26116658
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 1; n = 27)
Study: 26116658
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 2; n = 20)
Study: 26116658
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 3; n = 24)
Study: 26116658
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (all groups)
Study: 26119560
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin (BCG) administered according to the Southwest Oncology Group protocol.
Study: 26123421
Drug: Impulse oscillometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impulse oscillometry (IOS) during bronchial challenge testing with inhaled methacholine
Study: 26123421
Drug: Impulse oscillometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impulse oscillometry (IOS) during bronchial challenge testing with inhaled histamine
Study: 26123421
Drug: Spirometry (FEV1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirometry (FEV1) during bronchial challenge testing with inhaled methacholine
Study: 26123926
Drug: Tivantinib (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (360 mg po bid)
Study: 26123937
Drug: Single-tablet FTC-RPV-TDF
Normalized name: (-)-FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet FTC-RPV-TDF once daily for 28 days
Study: 26132314
Drug: Rituximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (500 mg/m2), two infusions two weeks apart, followed by maintenance infusions after 3, 6, 10 and 15 months
Study: 26133566
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg of ceftazidime + 500 mg of avibactam
Study: 26133566
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg of ceftazidime + 1000 mg of avibactam
Study: 26134834
Drug: Aggressive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive insulin delivery setting
Study: 26134834
Drug: Medium insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium insulin delivery setting
Study: 26134834
Drug: Conservative insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conservative insulin delivery setting
Study: 26135098
Drug: Polyethylene glycol-based
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-based electrolyte solutions (PEG-ELS)
Study: 26135681
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy in R1 patients
Study: 26135770
Drug: Threshold of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold of IMA >163 ng/mL
Study: 26137304
Drug: 25(OH)D ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D ≥ 75 nmol/L
Study: 26137358
Drug: Desvenlafaxine 25
Normalized name: DESVENLAFAXINE 25 mg ORAL TABLET, EXTENDED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 25 mg/d for 1 week followed by placebo for 3 weeks (taper)
Study: 26137358
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 4 weeks (abrupt discontinuation)
Study: 26137358
Drug: Desvenlafaxine 50
Normalized name: desvenlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50 mg/d for 4 weeks (no discontinuation)
Study: 26137532
Drug: Escitalopram, sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, sertraline or venlafaxine-ER for 8 weeks
Study: 26137971
Drug: Clindamycin and
Normalized name: clindamycin and benzoyl peroxide KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin and metronidazole followed by vaginal EcoVag® capsules for 5 consecutive days after each antibiotic treatment.
Study: 26137971
Drug: Clindamycin and
Normalized name: clindamycin and benzoyl peroxide KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin and metronidazole treatment together with prolonged administration of EcoVag® (10 consecutive days after each antibiotic treatment followed by weekly administration for next four months).
Study: 26137971
Drug: Extended fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended fluconazole and EcoVag® treatment.
Study: 26137971
Drug: Extended fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended fluconazole treatments only.
Study: 26139558
Drug: MABp1 (1.25mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABp1 (1.25mg/kg body weight, four biweekly intravenous infusions)
Study: 26140502
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n = 40)
Study: 26140502
Drug: Treatment crossover
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment crossover (n = 20)
Study: 26141713
Drug: Pressure from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure from doctors to reduce the delay between diagnosis and cancer treatment
Study: 26143264
Drug: Melanoma GVAX
Normalized name: Melanoma GVAX
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma GVAX (5E7 cells/cycle, 2E8 cells/cycle, or 2E8 cells/cycle with cyclophosphamide 200 mg/m2) administered intradermally once every 28 days for four cycles
Study: 26143343
Drug: Intravenous Sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Sildenafil
Study: 26148006
Drug: CLI patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLI patients not using aspirin
Study: 26148750
Drug: Icotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (125 mg orally 3 times/day) + Whole-Brain Radiotherapy (WBRT, 3.0 Gy per day, 5 days per week, to 30 Gy)
Study: 26148819
Drug: Subcutaneous implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous implantable cardioverter defibrillator (S-ICD) system
Study: 26149600
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine 20 mL injected bilaterally into the fascial plane between the multifidus and longissimus muscles
Study: 26150440
Drug: R-CHOP-14 at
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP-14 at end of treatment with central review
Study: 26152560
Drug: Catheter Contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter Contact Force (CF) ≥10 g
Study: 26152560
Drug: Increasing CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing CF at a location where initial CF was <10 g and CF increased ≥4.5 g in sinus rhythm or ≥8 g in atrial fibrillation
Study: 26152560
Drug: Increasing CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing CF at a location with initial CF <10 g and CF increased ≥8 g
Study: 26152560
Drug: Initial CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial CF ≥10 g
Study: 26153272
Drug: High-sensitivity C-reactive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity C-reactive protein, soluble E-selectin, and soluble intercellular adhesion molecule-1 in type 2 diabetes
Study: 26153726
Drug: Alpha-1 antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1 antitrypsin augmentation therapy
Study: 26153726
Drug: Matched PiZZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched PiZZ individuals not on augmentation therapy
Study: 26153726
Drug: PiMZ participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: PiMZ participants not on augmentation therapy
Study: 26155941
Drug: AMG 208
Normalized name: AMG-208
DrugBank: AMG-208 (DB08079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 208 (oral MET inhibitor)
Study: 26155957
Drug: Low albuminuria
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low albuminuria (LA, 10-29 mg/24 h)
Study: 26155957
Drug: Normal albuminuria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal albuminuria (NA, <10 mg/24 h)
Study: 26155957
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of anti-hyperglycaemic and anti-hypertensive agents
Study: 26156652
Drug: High-dose chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemoradiotherapy (60 Gy in 30 fractions to tumour, 50 Gy in 30 fractions to elective lymph node volumes, 5 Gy endorectal brachytherapy boost, and oral tegafur-uracil 300 mg/m(2) every weekday for 6 weeks)
Study: 26156652
Drug: High-dose chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemoradiotherapy
Study: 26158159
Drug: S-1 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 combination with oxaliplatin and oral leucovorin (SOL regimen)
Study: 26160357
Drug: Constant 24-h
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant 24-h infusion (16.5 μg/day)
Study: 26160357
Drug: Constant 7-day
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant 7-day infusion (25.5 μg/day in Cohort 2)
Study: 26160357
Drug: 7-day escalation
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day escalation regimen (ranging from 7 to 58.5 μg/day in Cohort 1)
Study: 26160357
Drug: 7-day escalation
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day escalation regimen (25.5-58.5 μg/day in Cohort 3)
Study: 26160744
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment (oseltamivir or zanamivir) in 474 patients.
Study: 26160880
Drug: Panobinostat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (10 mg) combined with idarubicin (8 mg/m(2) iv days 1-3) and cytarabine (100 mg/m(2) iv days 1-7) during induction, followed by panobinostat maintenance (40 mg po 3 days/week) every other week until progression.